Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05764733 · ClinicalTrials.gov registry record · Phase 4
Bone, Exercise, Alendronate, and Caloric Restriction
A Phase 4 study of Bone Loss, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 900
- Enrollment target
- 2
- Study locations
NCT05764733: Recruiting Phase 4 study of Bone Loss, sponsored by Wake Forest University Health Sciences.
NCT05764733 is a Phase 4 study of Bone Loss that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 900 participants, above the 198-participant average among 16 other Bone Loss trials with a reported enrollment target (355% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05764733, a Phase 4 study of Bone Loss, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 900 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.
Primary Outcome
Dual X-ray absorptiometry (DXA) derived
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Bisphosphonate
- BEHAVIORAL Resistance Training/Bone-Loading Exercise
Study Locations (2)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
North Carolina
- Atrium Health Wake Forest Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2023-06-08 |
| Est. Completion | 2027-09 |
| Phase | Phase 4 |
What NCT05764733 shows while recruiting
NCT05764733 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 198-participant average among 16 other Bone Loss trials with a reported enrollment target (355% higher).
The record links to 1 condition, with Bone Loss appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05764733 reports a single indexed study location in Colorado, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05764733 about?
NCT05764733 is a clinical study titled "Bone, Exercise, Alendronate, and Caloric Restriction". The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.
What is the current status of trial NCT05764733?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 900 participants. The study started on 2023-06-08. Estimated completion is 2027-09.
What conditions does trial NCT05764733 study?
This clinical trial studies the following conditions: Bone Loss.
What interventions are being tested in trial NCT05764733?
The interventions under investigation include: Placebo (OTHER), Bisphosphonate (DRUG), Resistance Training/Bone-Loading Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT05764733?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05764733 being conducted?
This trial has 2 study locations across Colorado, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05764733's enrollment target sits among peer trials
900 2nd of 16 the highest of 16 other Bone Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bone Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
RECRUITING · Phase 4
-
Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
COMPLETED · Phase 4
-
Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk
RECRUITING
-
Bone in CKD Alkali Response (BICARb Pilot Trial)
RECRUITING · Phase 2
-
Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor
RECRUITING · NA
-
Lutein, Zeaxathin, and Fish Oil Supplementation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI